Lv1
30 积分 2023-10-29 加入
Weight and mortality in people living with HIV and heart failure: Obesity paradox in the era of glucagon‐like peptide 1 (GLP‐1) receptor agonists and sodium‐glucose cotransporter‐2 (SGLT‐2) inhibitors
10天前
已完结
Robustness of randomized controlled trial evidence for SGLT2 inhibitors in heart failure with preserved and mildly reduced ejection fraction
10天前
已关闭
Glucose-lowering drugs or strategies, atherosclerotic cardiovascular events, and heart failure in people with or at risk of type 2 diabetes: an updated systematic review and meta-analysis of randomised cardiovascular outcome trials
10天前
已完结
Cardiovascular Outcomes of Sodium–Glucose Cotransporter 2 Inhibitors Across Body Mass Index Spectrum in Patients With Heart Failure: An Updated Systematic Review and Meta-Analysis
10天前
已完结
Obesity as a modifier of the cardiovascular effectiveness of sodium-glucose cotransporter-2 inhibitors in type 2 diabetes
1个月前
已完结
Sodium-glucose cotransporter 2 inhibitors and stroke risk in patients with diabetes and stroke risk factors: A real-world cohort study
1个月前
已完结
Association between sodium-glucose Co-transporter-2 inhibitor use and prognosis in underweight patients with diabetes mellitus and heart failure
1个月前
已完结
Heterogeneous cardiovascular effects of sodium-glucose cotransporter 2 inhibitors in type 2 diabetes: a causal forest and target trial emulation study
1个月前
已完结
Exploring the potential of finerenone in non-diabetic chronic kidney disease: a promising frontier
1个月前
已完结
Effectiveness and safety of finerenone in non-diabetic patients with IgA nephropathy
1个月前
已完结
皖公网安备34019202002308
